Dr. Henry Ji to Present at HC Wainwright BIOCONNECT Virtual Conference (January 10th – 13th)

Rhea-AI Summary

Sorrento Therapeutics (NASDAQ: SRNE) announced that Dr. Henry Ji, Chairman and CEO, will participate in the HC Wainwright BIOCONNECT Virtual Conference, with presentations available from January 10 to 13, 2022. Investors can register through a provided link. The company, known for its innovative therapies in cancer, pain management, autoimmune diseases, and COVID-19, is advancing treatments like resiniferatoxin for pain and novel therapies against coronaviruses.

Additional information, including updated corporate presentations, can be found at Sorrento Therapeutics.

SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:

• HC Wainwright BIOCONNECT Virtual Conference
  Presentation will be available on January 10 – 13, 2022.
  Registration link: Investors Registration BIOCONNECT

An updated corporate presentation will also be available at www.SorrentoTherapeutics.com.

About Sorrento Therapeutics, Inc. 

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™ and COVISTIX™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido^® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia (PHN). RTX has cleared for Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. SEMDEXA announced highly statistically significant positive top-line results from its Phase III Pivotal Trial C.L.E.A.R Program for its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica). ZTlido^® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and product candidates. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates’ and partners’ technologies and prospects and collaborations with partners; risks related to seeking regulatory approvals and conducting clinical trials; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 product candidates’ strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Contact: Dorman Followwill
Email: mediarelations@sorrentotherapeutics.com

Sorrento^® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2022 Sorrento Therapeutics, Inc. All Rights Reserved.

FAQ

What is the date of the HC Wainwright BIOCONNECT Virtual Conference for Sorrento Therapeutics?

The HC Wainwright BIOCONNECT Virtual Conference will take place from January 10 to 13, 2022.

Who will represent Sorrento Therapeutics at the HC Wainwright BIOCONNECT Conference?

Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, will represent the company.

Where can I register for the HC Wainwright BIOCONNECT Virtual Conference?

Investors can register for the conference through the registration link provided in the press release.

What therapies is Sorrento Therapeutics developing for COVID-19?

Sorrento is developing several antiviral therapies and vaccines against COVID-19, including COVI-AMG™, COVISHIELD™, and COVITRACK™.

What is resiniferatoxin, and how is Sorrento Therapeutics using it?

Resiniferatoxin is a non-opioid pain management small molecule that Sorrento is advancing for the treatment of intractable pain associated with cancer.